These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 7692148)

  • 21. Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease.
    He J; Whelton PK
    J Hypertens Suppl; 1999 Jun; 17(2):S7-13. PubMed ID: 10465061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The epidemiology of impaired glucose tolerance and hypertension.
    Kannel WB; Wilson PW; Zhang TJ
    Am Heart J; 1991 Apr; 121(4 Pt 2):1268-73. PubMed ID: 2008855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hypertension and hyperlipidemia].
    Hansen HS; Larsen ML
    Ugeskr Laeger; 2009 Jun; 171(24):2028-30. PubMed ID: 19523369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Left ventricular hypertrophy as a risk factor: the Framingham experience.
    Kannel WB
    J Hypertens Suppl; 1991 Dec; 9(2):S3-8; discussion S8-9. PubMed ID: 1838765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Heart, brain and hypertension].
    Lüscher TF; Sturzenegger M; Noll G
    Schweiz Med Wochenschr; 1996 Aug; 126(34):1449-56. PubMed ID: 8848709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study.
    Kannel WB; Wolf PA; Verter J; McNamara PM
    JAMA; 1970 Oct; 214(2):301-10. PubMed ID: 5469068
    [No Abstract]   [Full Text] [Related]  

  • 28. Measurement of cost-effectiveness of drug therapy: a review of the treatment of hypertension.
    Moulds RF
    Med J Aust; 1990 Aug; 153(S1):S4-6. PubMed ID: 2116584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of probability of stroke between the Copenhagen City Heart Study and the Framingham Study.
    Truelsen T; Lindenstrøm E; Boysen G
    Stroke; 1994 Apr; 25(4):802-7. PubMed ID: 8160224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Status of risk factors and their consideration in antihypertensive therapy.
    Kannel WB
    Am J Cardiol; 1987 Jan; 59(2):80A-90A. PubMed ID: 3544787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical heterogeneity of hypertension.
    Kannel WB
    Am J Hypertens; 1991 Mar; 4(3 Pt 1):283-7. PubMed ID: 2043309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal management of hypertensive patients with LVH and dyslipidaemia.
    Plouin PF
    Int J Clin Pract Suppl; 1998 Nov; 98():9-12. PubMed ID: 10344025
    [No Abstract]   [Full Text] [Related]  

  • 33. Risk factors in hypertension.
    Kannel WB
    J Cardiovasc Pharmacol; 1989; 13 Suppl 1():S4-10. PubMed ID: 2468976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease.
    Collins R; MacMahon S
    Br Med Bull; 1994 Apr; 50(2):272-98. PubMed ID: 8205459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
    Ariansen I; Reims HM; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Kjeldsen SE; Dahlöf B; Wachtell K
    Blood Press; 2012 Feb; 21(1):6-11. PubMed ID: 22070095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
    Bang CN; Devereux RB; Okin PM
    J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coronary heart disease risk factors in the elderly.
    Kannel WB
    Am J Geriatr Cardiol; 2002; 11(2):101-7. PubMed ID: 11872968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
    JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.